A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks® Test (www.aspirinworks.com) is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine (www.dlmlabs.com).
Dr. Joseph Musto, President and Medical Director of Diagnostic Laboratory Medicine, said the AspirinWorks Test is an important addition to the laboratory's testing services.
"We're pleased to be one of the first clinical laboratories in the region to offer this valuable test," said Dr. Musto. "AspirinWorks represents a simple, non-invasive, reliable test for physicians who realize that patients may respond differently to different doses of aspirin. This test truly helps physicians understand their patients' health on a personal level."
Aspirin, taken by millions of Americans every day to reduce the risk of heart attack and stroke, works by making blood platelets less sticky and thus less likely to form a blood clot. Major clinical studies have shown that as many as one in four patients are not adequately protected by their aspirin therapy.
The AspirinWorks Test, developed by Corgenix Medical Corp. (OTCQB: CONX.PK), determines the effect of aspirin on platelets by measuring the level of the biomarker called thromboxane B2. The higher the levels of thromboxane B2, the stickier the blood platelets and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy, which may be as simple as adjusting the dose.
AspirinWorks is the only FDA-cleared test that measures urinary thromboxane B2 to accurately determine aspirin effect in apparently healthy individuals. Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained at the doctor's office.
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes